O'Connor Daniel J.
- SEC CIK
- 0001376847
No open-market purchases or sales filed in the past year.
Current role at each company
- DMAC DiaMedica Therapeutics Inc.Directoras of Jun 3, 2026
- AMAM Ambrx Biopharma, Inc.President and CEOas of Mar 7, 2024
- SEEL Seelos Therapeutics, Inc.Directoras of Jan 8, 2024
- ZVSA ZyVersa Therapeutics, Inc.Director, 10% Owneras of Dec 14, 2022
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists O'Connor Daniel J. as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
AMAM Ambrx Biopharma, Inc.
President and CEO1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 31, 2023 (view filing) | Oct 27 | 4 days | O'Connor Daniel J.President and CEO | SSale | −50.0K | $9.82 | −$491.1K | −12.7%342.8K after | 10b5-1 |
SEEL Seelos Therapeutics, Inc.
Director1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 2, 2022 (view filing) | Jun 1 | 1 day | O'Connor Daniel J.Director | PPurchase | +16.0K | $0.61 | +$9.76K | New position16.0K after |